S. Vaziri, F. Lotfi Kashani, Masoumeh Karimian, A. Vaziri, Laya Nobakht, Y. Vaziri, R. Masoumi
Background: Mastectomy can change body image and affect the sexual activities of patients. Breast reconstruction is a way to reduce the sexual damage caused by mastectomy. Objectives: The present study aimed to compare body image and body exposure during sexual activity and sexual assertiveness among mastectomized women with/without mammaplasty and patients with cancer who volunteered for mammoplasty. Methods: This causal-comparative study was performed on the statistical population of mastectomized women with/without mammaplasty and patients who volunteered for mammoplasty within the age range of 25 - 55 years in Tehran, Iran, in 2018. The sample consisted of 37 women with mastectomy, 28 mastectomized women who volunteered for mammoplasty, and 31 women who underwent mammaplasty after mastectomy. The subjects were selected through convenience sampling in Tehran. All participants were asked to complete the Assessment of Body-Image Cognitive Distortions Questionnaire, the Body Exposure during Sexual Activities Questionnaire, and the Hurlbert Index of Sexual Assertiveness. The data were analyzed by analysis of variance using version 20th of SPSS software. Results: In terms of body-image cognitive distortions, there was no difference between the three groups. The women who underwent mammaplasty had less body exposure during sexual activity than patients who volunteered for mammoplasty (P < 0.01); however, there was no difference between the mastectomized patients and patients who underwent mammaplasty. Exposure to the body or anxious attentional focus on the body during sexual activity was reported frequently less in mastectomized women than in mammaplasty volunteers (P < 0.01). The sexual assertiveness of women who underwent reconstructive surgery was more than mastectomized women and volunteer patients for reconstructive surgery (P < 0.01). The mastectomized group had more sexual assertiveness than patients who volunteered for mammoplasty (P < 0.01). Conclusions: The results support the hypothesis that the issue of body image and its relationship with different aspects of sexual function is complex and requires considering different personality traits and factors as moderators. The importance that a woman places on the breast as a symbol of femininity and sexuality is one of the aforementioned factors. The purpose of reconstruction from the patient’s point of view and the importance that a woman gives to her appearance are other components that should be considered before proceeding with mammoplasty.
{"title":"Comparison of Body Image and Body Exposure During Sexual Activity and Sexual Assertiveness Among Mastectomized Women with/Without Mammaplasty and Mammaplasty Volunteer Patients","authors":"S. Vaziri, F. Lotfi Kashani, Masoumeh Karimian, A. Vaziri, Laya Nobakht, Y. Vaziri, R. Masoumi","doi":"10.5812/ijcm-117172","DOIUrl":"https://doi.org/10.5812/ijcm-117172","url":null,"abstract":"Background: Mastectomy can change body image and affect the sexual activities of patients. Breast reconstruction is a way to reduce the sexual damage caused by mastectomy. Objectives: The present study aimed to compare body image and body exposure during sexual activity and sexual assertiveness among mastectomized women with/without mammaplasty and patients with cancer who volunteered for mammoplasty. Methods: This causal-comparative study was performed on the statistical population of mastectomized women with/without mammaplasty and patients who volunteered for mammoplasty within the age range of 25 - 55 years in Tehran, Iran, in 2018. The sample consisted of 37 women with mastectomy, 28 mastectomized women who volunteered for mammoplasty, and 31 women who underwent mammaplasty after mastectomy. The subjects were selected through convenience sampling in Tehran. All participants were asked to complete the Assessment of Body-Image Cognitive Distortions Questionnaire, the Body Exposure during Sexual Activities Questionnaire, and the Hurlbert Index of Sexual Assertiveness. The data were analyzed by analysis of variance using version 20th of SPSS software. Results: In terms of body-image cognitive distortions, there was no difference between the three groups. The women who underwent mammaplasty had less body exposure during sexual activity than patients who volunteered for mammoplasty (P < 0.01); however, there was no difference between the mastectomized patients and patients who underwent mammaplasty. Exposure to the body or anxious attentional focus on the body during sexual activity was reported frequently less in mastectomized women than in mammaplasty volunteers (P < 0.01). The sexual assertiveness of women who underwent reconstructive surgery was more than mastectomized women and volunteer patients for reconstructive surgery (P < 0.01). The mastectomized group had more sexual assertiveness than patients who volunteered for mammoplasty (P < 0.01). Conclusions: The results support the hypothesis that the issue of body image and its relationship with different aspects of sexual function is complex and requires considering different personality traits and factors as moderators. The importance that a woman places on the breast as a symbol of femininity and sexuality is one of the aforementioned factors. The purpose of reconstruction from the patient’s point of view and the importance that a woman gives to her appearance are other components that should be considered before proceeding with mammoplasty.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"9 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87639064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Lotfi, Siamak Mashhady Rafie, S. Hesaraki, K. Amini
Background: Doxorubicin is a favorite drug for feasting many malignancies. All organs' hepatic toxic effects are destructive and lead to use with caution. Then, it is necessary to increase antioxidants accompanied with doxorubicin to reduce its toxicity. Vitamin E is an antioxidant with harmful consequences. Omega-3 is an antioxidant similarly. The healing capacity of Vitamin E- Omega-3 was investigated together against doxorubicin. Methods: Thirty balb/c mice have divided a weight of 25 g into five equal groups of six mice each. The groups were classified as Control: normal saline; DOX: Doxorubicin; Vitamin E: Vitamin E + DOX; Omega-3; Omega-3 + DOX; Both Vitamin E- Omega-3 + DOX. The histopathology was set to describe vacuolar degeneration, inflammation, and necrosis. Immunohistochemistry was performed to estimate the expression of tumor necrosis factor (TNFα), demonstrating the inflammation. Results: DOX-induced hepatic injury and increased TNF-α expression were seen more than alone when co-administered with vitamin E and omega-3. A significant decrease was shown in the ALT, AST, GGT, and ALP levels compared to the control. The Glutathione peroxidase and Catalase enzyme activities were higher in the co-administered Vitamin E- Omega-3 group than that received Vit E or Omega-3. Conclusions: Co-administration of Vitamin E and Omega-3 have a more repair capacity with controlling effects on Doxorubicin-induced liver toxicity.
{"title":"Protective Effects of Coadministration of the Vitamin E and Omega-3 on Doxorubicin-Induced Hepatotoxicity in Mice","authors":"A. Lotfi, Siamak Mashhady Rafie, S. Hesaraki, K. Amini","doi":"10.5812/ijcm-121766","DOIUrl":"https://doi.org/10.5812/ijcm-121766","url":null,"abstract":"Background: Doxorubicin is a favorite drug for feasting many malignancies. All organs' hepatic toxic effects are destructive and lead to use with caution. Then, it is necessary to increase antioxidants accompanied with doxorubicin to reduce its toxicity. Vitamin E is an antioxidant with harmful consequences. Omega-3 is an antioxidant similarly. The healing capacity of Vitamin E- Omega-3 was investigated together against doxorubicin. Methods: Thirty balb/c mice have divided a weight of 25 g into five equal groups of six mice each. The groups were classified as Control: normal saline; DOX: Doxorubicin; Vitamin E: Vitamin E + DOX; Omega-3; Omega-3 + DOX; Both Vitamin E- Omega-3 + DOX. The histopathology was set to describe vacuolar degeneration, inflammation, and necrosis. Immunohistochemistry was performed to estimate the expression of tumor necrosis factor (TNFα), demonstrating the inflammation. Results: DOX-induced hepatic injury and increased TNF-α expression were seen more than alone when co-administered with vitamin E and omega-3. A significant decrease was shown in the ALT, AST, GGT, and ALP levels compared to the control. The Glutathione peroxidase and Catalase enzyme activities were higher in the co-administered Vitamin E- Omega-3 group than that received Vit E or Omega-3. Conclusions: Co-administration of Vitamin E and Omega-3 have a more repair capacity with controlling effects on Doxorubicin-induced liver toxicity.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"17 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85537444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nasrin Bazgir, F. Taghinezhad, H. Nourmohammadi, Golnaz Azami, I. Ahmadi, A. Mozafari
Background: Patients with cancer are potentially vulnerable to COVID-19 infection due to the immune-compromised state of cancer or its treatment complications. Objectives: This study compared the COVID-19 mortality rate in cancer patients with and without a history of chemotherapy. Methods: This registry-based cohort study launched from March 2020 to March 2021 contains 2350 records in which 64 COVID-19 patients with cancer were included, of which 27 patients underwent the chemotherapy plan within eight weeks before confirmed COVID-19. In addition, age and sex were matched in patients without a history of cancer as a control group. Two groups of cancer patients with and without a history of chemotherapy compared to the control group using cox proportional hazard regression models in Stata.10 software. Results: Patients with cancer had a higher hazard for in-hospital mortality from COVID-19 infection (adjusted HR; 2.27, 95% CI: 1.25 - 4.13, P = 0.007) after adjusting for age, sex, body mass index (BMI), and co-morbidities. Our result showed no significant association between chemotherapy and control groups (adjusted HR; 1.65, 95% CI: 0.60 - 4.56, P = 0.33). Conclusions: Patients with cancer faced a risk of mortality from COVID-19 two times higher than those without cancer. However, chemotherapy did not increase the mortality following COVID-19 infection.
背景:由于癌症的免疫功能低下状态或其治疗并发症，癌症患者可能容易感染COVID-19。目的:本研究比较有和无化疗史的癌症患者的COVID-19死亡率。方法:本研究于2020年3月至2021年3月启动，纳入2350例病例，其中64例2019冠状病毒病癌症患者，其中27例患者在确诊前8周内接受化疗方案。此外，在没有癌症病史的患者中，年龄和性别相匹配，作为对照组。采用Stata.10软件中的cox比例风险回归模型，将两组有和无化疗史的癌症患者与对照组进行比较。结果:癌症患者因COVID-19感染而住院死亡的风险较高(调整HR;2.27, 95% CI: 1.25 - 4.13, P = 0.007)，校正了年龄、性别、体重指数(BMI)和合并症。我们的结果显示化疗组与对照组之间无显著关联(校正HR;1.65, 95% ci: 0.60 - 4.56, p = 0.33)。结论:癌症患者的COVID-19死亡风险是非癌症患者的两倍。然而，化疗并没有增加COVID-19感染后的死亡率。
{"title":"Comparing the COVID-19 Mortality Rate in Cancer Patients with and Without a History of Chemotherapy","authors":"Nasrin Bazgir, F. Taghinezhad, H. Nourmohammadi, Golnaz Azami, I. Ahmadi, A. Mozafari","doi":"10.5812/ijcm-128404","DOIUrl":"https://doi.org/10.5812/ijcm-128404","url":null,"abstract":"Background: Patients with cancer are potentially vulnerable to COVID-19 infection due to the immune-compromised state of cancer or its treatment complications. Objectives: This study compared the COVID-19 mortality rate in cancer patients with and without a history of chemotherapy. Methods: This registry-based cohort study launched from March 2020 to March 2021 contains 2350 records in which 64 COVID-19 patients with cancer were included, of which 27 patients underwent the chemotherapy plan within eight weeks before confirmed COVID-19. In addition, age and sex were matched in patients without a history of cancer as a control group. Two groups of cancer patients with and without a history of chemotherapy compared to the control group using cox proportional hazard regression models in Stata.10 software. Results: Patients with cancer had a higher hazard for in-hospital mortality from COVID-19 infection (adjusted HR; 2.27, 95% CI: 1.25 - 4.13, P = 0.007) after adjusting for age, sex, body mass index (BMI), and co-morbidities. Our result showed no significant association between chemotherapy and control groups (adjusted HR; 1.65, 95% CI: 0.60 - 4.56, P = 0.33). Conclusions: Patients with cancer faced a risk of mortality from COVID-19 two times higher than those without cancer. However, chemotherapy did not increase the mortality following COVID-19 infection.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"132 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79225472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zeinabsadat Mohammadi, Mohammad Mostakhdem Hashemi, Marie Saghaeian Jazi
Background: Spironolactone is a conventional drug widely in use for the treatment of heart failure and hypertension patients. On the other side recent studies have reported spironolactone can prevent growth and drug resistance in cancer stem cells (CSCs), by inhibiting DNA double-strand break (DSB) repair; suggesting its potential application in cancer therapy. Objectives: Our study aimed at assessing the potential cytotoxicity of spironolactone in human U87-MG glioblastoma cells. Methods: different concentrations of spironolactone (0 - 50 μM) for 48 and 72 h were used for treatment. Cell viability assay was carried out by the 4, 5-dimethylthiazole-2-yl, 2, 5-diphenyl tetrazolium (MTT) method. Apoptosis was evaluated using annexin V/PI staining and flow cytometry and colorimetric measurement of caspase 8 and 9 activity. Results: our findings showed a significant dose-dependent cytotoxic effect of spironolactone with maximum effect in 30 μM (P-value < 0.05). Spironolactone can induce approximately 20% apoptotic cell death in U87-MG cancer cells which were mainly related to early apoptotic cells. Indeed, the activity of caspase 8 and 9 was significantly elevated in spironolactone-treated cells compared to mock control. Conclusions: Findings showed the cytotoxic effect of spironolactone in U87-MG glioblastoma cancer cells in a mechanism dependent on apoptosis cell death induction. Our findings suggest the potential application of spironolactone in the treatment of glioblastoma in vitro.
{"title":"Spironolactone Induces Apoptotic Cell Death in Human Glioblastoma U87-MG Cancer Cells","authors":"Zeinabsadat Mohammadi, Mohammad Mostakhdem Hashemi, Marie Saghaeian Jazi","doi":"10.5812/ijcm-128738","DOIUrl":"https://doi.org/10.5812/ijcm-128738","url":null,"abstract":"Background: Spironolactone is a conventional drug widely in use for the treatment of heart failure and hypertension patients. On the other side recent studies have reported spironolactone can prevent growth and drug resistance in cancer stem cells (CSCs), by inhibiting DNA double-strand break (DSB) repair; suggesting its potential application in cancer therapy. Objectives: Our study aimed at assessing the potential cytotoxicity of spironolactone in human U87-MG glioblastoma cells. Methods: different concentrations of spironolactone (0 - 50 μM) for 48 and 72 h were used for treatment. Cell viability assay was carried out by the 4, 5-dimethylthiazole-2-yl, 2, 5-diphenyl tetrazolium (MTT) method. Apoptosis was evaluated using annexin V/PI staining and flow cytometry and colorimetric measurement of caspase 8 and 9 activity. Results: our findings showed a significant dose-dependent cytotoxic effect of spironolactone with maximum effect in 30 μM (P-value < 0.05). Spironolactone can induce approximately 20% apoptotic cell death in U87-MG cancer cells which were mainly related to early apoptotic cells. Indeed, the activity of caspase 8 and 9 was significantly elevated in spironolactone-treated cells compared to mock control. Conclusions: Findings showed the cytotoxic effect of spironolactone in U87-MG glioblastoma cancer cells in a mechanism dependent on apoptosis cell death induction. Our findings suggest the potential application of spironolactone in the treatment of glioblastoma in vitro.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"4 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79366375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Z. Shiravani, N. Namazi, Masooumeh Hashemi, Fatemesadat Najib, Mojgan Hajisafari Tafti
Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient characteristic besides to the factors affecting the recurrence rate among different races. Objectives: The aim of this study is to evaluate clinicopathologic features of the tumor to discover the controversies on the topic. Methods: Medical data of the all referred patients to Motahari clinic from January 2010 till October 2020 were recorded. Patient clinicopathologic characteristics affecting on outcome were evaluated. By using SPSS software, data were tested by chi-square and fish exact test. Also, log rank test was used for survival analysis Results: Totally 145 patients were enrolled. 61.4% versus 38.6% of the patients underwent fertility sparing surgery and radical surgery respectively with common characteristics of mostly belong to stage 1A disease (61.8% vs. 66.1%), unilateral (93.3% vs. 89.3%), serous histology (51.7% vs. 66.1%). The characteristics were different in the aspects of age and tumor size. In the aspect of recurrence rate, higher FIGO stage, younger age, tumor size less than 10cm, performing laparoscopy and fertility sparing surgery were with higher rate of recurrence (P-value < 0.05) while histology type of the tumor, lateralization, micropapillary, microinvasion, noninvasive peritoneal implants, receiving adjuvant chemotherapy and performing lymphadenectomy were not statistically significant for recurrence (P-value > 0.05). Two patients had malignant transformation. Conclusions: Fertility sparing surgery and higher FIGO stages are with more recurrence rate in Borderline ovarian tumor patients. However, micropapillary, microinvasion were not significantly with higher recurrence rate in our study but they are challenging issues in border line ovarian tumors among different studies. Due to most prevalence of border line ovarian tumors in young women and desire of fertility preservation, we should notice more to clinicopathologic and surgery types affecting on recurrence of BOTs.
{"title":"Evaluation of Clinicopathologic Factors and Surgery Management on Borderline Ovarian Tumor Outcomes","authors":"Z. Shiravani, N. Namazi, Masooumeh Hashemi, Fatemesadat Najib, Mojgan Hajisafari Tafti","doi":"10.5812/ijcm-114910","DOIUrl":"https://doi.org/10.5812/ijcm-114910","url":null,"abstract":"Background: Borderline ovarian tumor (BOT) is a tumor most prevalent in young woman with desire to fertility. There are some controversies on the patient characteristic besides to the factors affecting the recurrence rate among different races. Objectives: The aim of this study is to evaluate clinicopathologic features of the tumor to discover the controversies on the topic. Methods: Medical data of the all referred patients to Motahari clinic from January 2010 till October 2020 were recorded. Patient clinicopathologic characteristics affecting on outcome were evaluated. By using SPSS software, data were tested by chi-square and fish exact test. Also, log rank test was used for survival analysis Results: Totally 145 patients were enrolled. 61.4% versus 38.6% of the patients underwent fertility sparing surgery and radical surgery respectively with common characteristics of mostly belong to stage 1A disease (61.8% vs. 66.1%), unilateral (93.3% vs. 89.3%), serous histology (51.7% vs. 66.1%). The characteristics were different in the aspects of age and tumor size. In the aspect of recurrence rate, higher FIGO stage, younger age, tumor size less than 10cm, performing laparoscopy and fertility sparing surgery were with higher rate of recurrence (P-value < 0.05) while histology type of the tumor, lateralization, micropapillary, microinvasion, noninvasive peritoneal implants, receiving adjuvant chemotherapy and performing lymphadenectomy were not statistically significant for recurrence (P-value > 0.05). Two patients had malignant transformation. Conclusions: Fertility sparing surgery and higher FIGO stages are with more recurrence rate in Borderline ovarian tumor patients. However, micropapillary, microinvasion were not significantly with higher recurrence rate in our study but they are challenging issues in border line ovarian tumors among different studies. Due to most prevalence of border line ovarian tumors in young women and desire of fertility preservation, we should notice more to clinicopathologic and surgery types affecting on recurrence of BOTs.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"11 5 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74625197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Ebrahimpour, M. Chehrassan, A. Karimi, A. Sabaghzadeh, M. Jafari Kafiabadi, F. Biglari, Mehdi Azizmohammad Looha, A. Nakhostin-Ansari, M. Sadighi, M. Akbari
Background: Chondrosarcoma is regarded as the second most common primary bone malignancy following osteosarcoma. Objectives: The present study aimed at determining the epidemiology, incidence, and survival rate of chondrosarcoma in the Iranian population, according to the Iran National Cancer Registry (INCR). Methods: In an epidemiological study, patients with limb chondrosarcoma were evaluated based on INCR data between 2008 and 2015. Data included patients’ demographic characteristics, date of diagnosis, location of the tumor, patient’s survival, and type of tumor based on the International Classification of Diseases for Oncology (ICD-O-3; first revision, third edition) were collected and analyzed. Results: Out of 732 enrolled patients, 425 patients (58.06%) were male and 307 (41.94%) were female with a mean age of 44.08 (SD = 19.31) and 45.06 (SD = 18.72), respectively. Age-standardized incidence rates (ASIR) were 1.73 and 1.27 per 1 million person-years for males and females, respectively. Conventional chondrosarcoma was the most common subtype with ASIR 1.28 and constituted 84.7% of patients with chondrosarcoma. About 71.03% of all Chondrosarcoma patients (70.35% of males and 71.99% of females) were between 20 to 59 years old. The 1-, 3-, 5-, and 7-year survival rates of patients were 0.87, 0.73, 0.57, and 0.47, respectively. Also, the mean survival time was 6.12 years (95% CI: 5.85 - 7.39). Conclusions: The incidence of chondrosarcoma in Iran is not as high as in other countries, but as patients are younger in Iran, the survival rate is worse compared to other countries. Therefore, better case findings and better care are needed to improve the patients' outcomes in Iran.
{"title":"The Epidemiology of Chondrosarcoma in Iran Based on Iran National Cancer Registry","authors":"A. Ebrahimpour, M. Chehrassan, A. Karimi, A. Sabaghzadeh, M. Jafari Kafiabadi, F. Biglari, Mehdi Azizmohammad Looha, A. Nakhostin-Ansari, M. Sadighi, M. Akbari","doi":"10.5812/ijcm-119308","DOIUrl":"https://doi.org/10.5812/ijcm-119308","url":null,"abstract":"Background: Chondrosarcoma is regarded as the second most common primary bone malignancy following osteosarcoma. Objectives: The present study aimed at determining the epidemiology, incidence, and survival rate of chondrosarcoma in the Iranian population, according to the Iran National Cancer Registry (INCR). Methods: In an epidemiological study, patients with limb chondrosarcoma were evaluated based on INCR data between 2008 and 2015. Data included patients’ demographic characteristics, date of diagnosis, location of the tumor, patient’s survival, and type of tumor based on the International Classification of Diseases for Oncology (ICD-O-3; first revision, third edition) were collected and analyzed. Results: Out of 732 enrolled patients, 425 patients (58.06%) were male and 307 (41.94%) were female with a mean age of 44.08 (SD = 19.31) and 45.06 (SD = 18.72), respectively. Age-standardized incidence rates (ASIR) were 1.73 and 1.27 per 1 million person-years for males and females, respectively. Conventional chondrosarcoma was the most common subtype with ASIR 1.28 and constituted 84.7% of patients with chondrosarcoma. About 71.03% of all Chondrosarcoma patients (70.35% of males and 71.99% of females) were between 20 to 59 years old. The 1-, 3-, 5-, and 7-year survival rates of patients were 0.87, 0.73, 0.57, and 0.47, respectively. Also, the mean survival time was 6.12 years (95% CI: 5.85 - 7.39). Conclusions: The incidence of chondrosarcoma in Iran is not as high as in other countries, but as patients are younger in Iran, the survival rate is worse compared to other countries. Therefore, better case findings and better care are needed to improve the patients' outcomes in Iran.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"14 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81334212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amirreza Manteghinejad, S. Arabzadeh, Zahra Rezaian, M. Sharifi, S. Haghjooy Javanmard
Background: Patients with cancer are at an increased risk of mortality from COVID-19 infection. So, they are prioritized for vaccination. However, there is limited data about the immunogenicity, safety, and effectiveness of inactivated vaccines in preventing COVID-19 infection, hospitalization, and mortality in patients with cancer. Objectives: This study aimed to report the clinical characteristics of patients who had a positive PCR test after being fully vaccinated with the Sinopharm BIBP Vaccine. Methods: In this retrospective study, the data of patients with cancer were extracted from the electronic health records of a cancer center in Isfahan, Iran. All COVID-19 data from Isfahan province also was collected by Isfahan COVID-19 Registry (I-CORE). We described the clinical characteristics of patients with cancer who have a positive test more than14 days after the second dose. Results: Two hundred twenty-two patients with cancer had at least one positive PCR test after the start of the COVID-19 vaccination. Of these, 9 (4.1%) breakthrough infections have occurred. Six (67%) of them had hematological malignancies. Six (67%) were hospitalized and 3 (33%) patients died. Two of them had recent chemotherapy and have hematological malignancies. Conclusions: Vaccination is a good way to protect the population from COVID-19 complications and mortality, but it should be considered that fully-vaccinated patients with cancer are at risk of severe outcomes. Nevertheless, prioritizing cancer patients, especially those with hematological malignancies, or receiving chemotherapies for booster vaccines and studying the effectiveness of each COVID-19 vaccine for patients with cancer should be considered.
{"title":"COVID-19 Breakthrough Infections among Patients with Cancer Receiving Sinopharm BIBP Vaccine","authors":"Amirreza Manteghinejad, S. Arabzadeh, Zahra Rezaian, M. Sharifi, S. Haghjooy Javanmard","doi":"10.5812/ijcm-123887","DOIUrl":"https://doi.org/10.5812/ijcm-123887","url":null,"abstract":"Background: Patients with cancer are at an increased risk of mortality from COVID-19 infection. So, they are prioritized for vaccination. However, there is limited data about the immunogenicity, safety, and effectiveness of inactivated vaccines in preventing COVID-19 infection, hospitalization, and mortality in patients with cancer. Objectives: This study aimed to report the clinical characteristics of patients who had a positive PCR test after being fully vaccinated with the Sinopharm BIBP Vaccine. Methods: In this retrospective study, the data of patients with cancer were extracted from the electronic health records of a cancer center in Isfahan, Iran. All COVID-19 data from Isfahan province also was collected by Isfahan COVID-19 Registry (I-CORE). We described the clinical characteristics of patients with cancer who have a positive test more than14 days after the second dose. Results: Two hundred twenty-two patients with cancer had at least one positive PCR test after the start of the COVID-19 vaccination. Of these, 9 (4.1%) breakthrough infections have occurred. Six (67%) of them had hematological malignancies. Six (67%) were hospitalized and 3 (33%) patients died. Two of them had recent chemotherapy and have hematological malignancies. Conclusions: Vaccination is a good way to protect the population from COVID-19 complications and mortality, but it should be considered that fully-vaccinated patients with cancer are at risk of severe outcomes. Nevertheless, prioritizing cancer patients, especially those with hematological malignancies, or receiving chemotherapies for booster vaccines and studying the effectiveness of each COVID-19 vaccine for patients with cancer should be considered.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"49 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72513298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Numerous studies have shown an association between hormones secreted by adipose tissues and cancer development. Objectives: This study aimed at investigating the effect of body mass index (BMI) and genetic variation of leptin and adiponectin on serum concentrations of leptin, adiponectin, and estradiol among untreated breast cancer. Methods: This case-control study was performed on 350 women (175 women with breast cancer and 175 healthy controls), who had not taken any medications. Serum levels of estradiol (17-beta estradiol), leptin, and adiponectin were measured, using the ELISA technique. Single-nucleotide polymorphisms of leptin gene (LepG2548A), leptin receptor (Q223, K109R, and K656N), and adiponectin gene (T45G, G276T, C11377G, and 11391A) in blood-isolated DNA were evaluated, using RFLP-PCR technique. Results: Body mass index can affect serum concentrations of hormones and is associated with breast cancer. Also, except for adiponectin C11377G polymorphism, other all genetic variations showed significant relationships with breast cancer. In both groups, BMI was significantly correlated with the mean serum concentrations of hormones, and the risk of breast cancer increased in G2548A, Q223R, K656N, and G276T polymorphisms. The effect of risk allele genotypes on serum concentration of hormones showed that changes in serum concentration of estrogen and leptin in all studied polymorphisms were associated with breast cancer in postmenopausal women. But adiponectin level was only affected by polymorphisms K109R, K656N, and G276 and G11391A. Conclusions: High BMI and genetic variation can affect cancer development by changing the serum concentrations of hormones in different genotypes. Studying various populations’ genetics and lifestyle can help definitive conclusions about genetics and obesity.
{"title":"The Effects of BMI and Genetic Variation of Adipokines on Serum Concentrations of Hormones in Untreated Individuals with Breast Cancer; a Pilot Study","authors":"Zahra Tahmasebi Fard","doi":"10.5812/ijcm-120259","DOIUrl":"https://doi.org/10.5812/ijcm-120259","url":null,"abstract":"Background: Numerous studies have shown an association between hormones secreted by adipose tissues and cancer development. Objectives: This study aimed at investigating the effect of body mass index (BMI) and genetic variation of leptin and adiponectin on serum concentrations of leptin, adiponectin, and estradiol among untreated breast cancer. Methods: This case-control study was performed on 350 women (175 women with breast cancer and 175 healthy controls), who had not taken any medications. Serum levels of estradiol (17-beta estradiol), leptin, and adiponectin were measured, using the ELISA technique. Single-nucleotide polymorphisms of leptin gene (LepG2548A), leptin receptor (Q223, K109R, and K656N), and adiponectin gene (T45G, G276T, C11377G, and 11391A) in blood-isolated DNA were evaluated, using RFLP-PCR technique. Results: Body mass index can affect serum concentrations of hormones and is associated with breast cancer. Also, except for adiponectin C11377G polymorphism, other all genetic variations showed significant relationships with breast cancer. In both groups, BMI was significantly correlated with the mean serum concentrations of hormones, and the risk of breast cancer increased in G2548A, Q223R, K656N, and G276T polymorphisms. The effect of risk allele genotypes on serum concentration of hormones showed that changes in serum concentration of estrogen and leptin in all studied polymorphisms were associated with breast cancer in postmenopausal women. But adiponectin level was only affected by polymorphisms K109R, K656N, and G276 and G11391A. Conclusions: High BMI and genetic variation can affect cancer development by changing the serum concentrations of hormones in different genotypes. Studying various populations’ genetics and lifestyle can help definitive conclusions about genetics and obesity.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"17 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76742636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The role of tumor-associated tissue eosinophils and mast cells in the biological behavior of tumors remains unclear. Objectives: This study was performed to compare the eosinophil and mast cell counts in the cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) of the head and neck and to evaluate their relationship with clinicopathologic factors. Methods: The current descriptive-analytical study was conducted on the histopathologic slides of 46 BCC and 30 cSCC samples prepared by using Sirius red and toluidine blue staining techniques for eosinophil and mast cell counts, respectively. The data were analyzed, using Pearson’s correlation, t test, and ANOVA test. Results: The BCC and cSCC samples had mean eosinophil counts of 35.43 ± 35 and 331.27 ± 321.68 eosinophil/10 HPF, respectively, and this difference was statistically significant (P = 0.001). The levels of the mast cell infiltration were obtained as 55.33 ± 39.90 and 63.67 ± 40.86 in BCC and cSCC, respectively. However, this variable was not significantly different between the two groups of BCC and cSCC samples (P = 0.380). In addition, the mean eosinophil and mast cell counts were higher in cSCC grade 3 than in other grades; however, this difference was statistically significant only for the mast cells. Furthermore, the mean eosinophil/mast cell count in cSCC and BCC showed no significant relationship with age and gender. Conclusions: Considering the greater presence of eosinophils in cSCC than in BCC, eosinophils may be concluded to be among the factors responsible for more biologically and clinically invasive behaviors of cSCC, compared to those of BCC.
{"title":"Comparative Study of Immune Cells Infiltration in Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma of the Head and Neck","authors":"Shirin Saravani, Hamideh Kadeh, Mahya Tavakoli Amin, Narges Ghavidel","doi":"10.5812/ijcm-117673","DOIUrl":"https://doi.org/10.5812/ijcm-117673","url":null,"abstract":"Background: The role of tumor-associated tissue eosinophils and mast cells in the biological behavior of tumors remains unclear. Objectives: This study was performed to compare the eosinophil and mast cell counts in the cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) of the head and neck and to evaluate their relationship with clinicopathologic factors. Methods: The current descriptive-analytical study was conducted on the histopathologic slides of 46 BCC and 30 cSCC samples prepared by using Sirius red and toluidine blue staining techniques for eosinophil and mast cell counts, respectively. The data were analyzed, using Pearson’s correlation, t test, and ANOVA test. Results: The BCC and cSCC samples had mean eosinophil counts of 35.43 ± 35 and 331.27 ± 321.68 eosinophil/10 HPF, respectively, and this difference was statistically significant (P = 0.001). The levels of the mast cell infiltration were obtained as 55.33 ± 39.90 and 63.67 ± 40.86 in BCC and cSCC, respectively. However, this variable was not significantly different between the two groups of BCC and cSCC samples (P = 0.380). In addition, the mean eosinophil and mast cell counts were higher in cSCC grade 3 than in other grades; however, this difference was statistically significant only for the mast cells. Furthermore, the mean eosinophil/mast cell count in cSCC and BCC showed no significant relationship with age and gender. Conclusions: Considering the greater presence of eosinophils in cSCC than in BCC, eosinophils may be concluded to be among the factors responsible for more biologically and clinically invasive behaviors of cSCC, compared to those of BCC.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"4 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88596790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Sadighi, Morteza Ghassed, Z. Hosseini, A. Alikhassi
Background: Developing asymmetries are uncommon mammographic findings with a chance of being associated with malignancy. Objectives: The current study aimed at correlating ultrasound, magnetic resonance imaging (MRI) findings, and histopathology of patients with developing focal asymmetry in opportunist screening mammograms setting, and presents a diagnostic approach to developing asymmetry. Methods: This was a cross-sectional study on a database of opportunist screening mammography at the Breast Clinic, Cancer Center, at Tehran University of Medical Sciences from January 2017 to December 2018. Mammogram screenings (n = 12,169) were evaluated for developing asymmetry. Findings of mammography, ultrasound, MRI findings, and histopathology of patients with developing asymmetry were collected and analyzed. Results: Fifty-four cases (0.44%) had developed asymmetry in screening mammograms. After excluding 18 patients with considering exclusion criteria, the data of 36 patients were analyzed. The summation artifact was the etiology of developing asymmetry in 11 (30.5%) patients. Ultrasound was performed in 28 patients, and 14 (38.8%) patients had no correlated findings. All 3 malignant cases had ultrasound correlates, and a significant association existed between sonography and the risk of malignancy in patients having developing asymmetry (P = 0.003). Three malignant cases of the study underwent MRI, 1 with segmental clumped non-mass enhancement, and 2 showed a mass with rim enhancement. A significant association was revealed between a family history of breast cancer (P = 0.04) and developing asymmetry. The positive predictive value of developing asymmetry for malignancy was 8.3%. Conclusions: Patients having developing asymmetry should be evaluated for malignancy, using supplementary techniques, such as additional mammographic views, ultrasound primarily, or MRI. A biopsy is required for indeterminate findings.
{"title":"Diagnostic Approach to Developing Asymmetry in Opportunist Screening Mammography; Correlation of Ultrasound, Magnetic Resonance Imaging, and Histopathologic Findings with Developing Asymmetry: A Cross-sectional Study","authors":"N. Sadighi, Morteza Ghassed, Z. Hosseini, A. Alikhassi","doi":"10.5812/ijcm-122779","DOIUrl":"https://doi.org/10.5812/ijcm-122779","url":null,"abstract":"Background: Developing asymmetries are uncommon mammographic findings with a chance of being associated with malignancy. Objectives: The current study aimed at correlating ultrasound, magnetic resonance imaging (MRI) findings, and histopathology of patients with developing focal asymmetry in opportunist screening mammograms setting, and presents a diagnostic approach to developing asymmetry. Methods: This was a cross-sectional study on a database of opportunist screening mammography at the Breast Clinic, Cancer Center, at Tehran University of Medical Sciences from January 2017 to December 2018. Mammogram screenings (n = 12,169) were evaluated for developing asymmetry. Findings of mammography, ultrasound, MRI findings, and histopathology of patients with developing asymmetry were collected and analyzed. Results: Fifty-four cases (0.44%) had developed asymmetry in screening mammograms. After excluding 18 patients with considering exclusion criteria, the data of 36 patients were analyzed. The summation artifact was the etiology of developing asymmetry in 11 (30.5%) patients. Ultrasound was performed in 28 patients, and 14 (38.8%) patients had no correlated findings. All 3 malignant cases had ultrasound correlates, and a significant association existed between sonography and the risk of malignancy in patients having developing asymmetry (P = 0.003). Three malignant cases of the study underwent MRI, 1 with segmental clumped non-mass enhancement, and 2 showed a mass with rim enhancement. A significant association was revealed between a family history of breast cancer (P = 0.04) and developing asymmetry. The positive predictive value of developing asymmetry for malignancy was 8.3%. Conclusions: Patients having developing asymmetry should be evaluated for malignancy, using supplementary techniques, such as additional mammographic views, ultrasound primarily, or MRI. A biopsy is required for indeterminate findings.","PeriodicalId":44764,"journal":{"name":"International Journal of Cancer Management","volume":"36 1","pages":""},"PeriodicalIF":0.7,"publicationDate":"2022-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87172086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：